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1  | BACKGROUND
Cyclic AMP– dependent protein kinase A (PKA) and protein phos-
phatase 1 (PP1) are multifunctional proteins involved in numerous 
essential signalling pathways that modulate physiological and patho-
logical functions which have been implicated in cancer development 
and progression. Both PKA and PP1 are oligomeric enzymes com-
posed of catalytic and regulatory subunits. PKA is a heterotetramer 
of two catalytic (encoded by PRKACA, PRKACB, PRKACG) and two 
regulatory (encoded by PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B) 
subunits. PKA is involved in a wide array of cellular processes, in-
cluding metabolism, gene expression and apoptosis. PKA is also ex-
pected to play a variety of roles dictated by cellular context due to 
its influence of multiple cellular signalling pathways. Interestingly, 
in breast cancer, PKA is capable of phosphorylating serine 305 of 
oestrogen receptor α (ERα) to induce tamoxifen resistance and alter 
the transcriptome through redirection of ERα to new transcriptional 
start sites.1,2 Low PRKAR1A/high SRC mRNA has been shown to 
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Abstract
Cyclic AMP– dependent protein kinase A (PKA) and protein phosphatase 1 (PP1) are 
proteins involved in numerous essential signalling pathways that modulate physiolog-
ical and pathological functions. Both PP1 and PKA can be inhibited by dopamine- and 
cAMP- regulated phosphoprotein 32 kD (DARPP- 32). Using immunohistochemistry, 
PKA and PP1 expression was determined in a large primary breast tumour cohort 
to evaluate associations between clinical outcome and clinicopathological criteria 
(n > 1100). In addition, mRNA expression of PKA and PP1 subunits was assessed in 
the METABRIC data set (n = 1980). Low protein expression of PKA was significantly 
associated with adverse survival of breast cancer patients; interestingly, this relation-
ship was stronger in ER- positive breast cancer patients. PP1 protein expression was 
not associated with patient survival. PKA and PP1 subunit mRNA was also assessed; 
PPP1CA, PRKACG and PRKAR1B were associated with breast cancer– specific survival. 
In patients with high expression of DARPP- 32, low expression of PP1 was associated 
with adverse survival when compared to high expression in the same group. PKA ex-
pression and PP1 expression are of significant interest in cancer as they are involved 
in a wide array of cellular processes, and these data indicate PKA and PP1 may play 
an important role in patient outcome.
K E Y W O R D S
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define basal- like and HER2- positive breast cancers with a worse 
clinical outcome,3 and PKA activity has also been implicated in HER2 
resistance in vitro, in particular down- regulation of the PKA- RIIα 
subunit.4
Like PKA, PP1 is a multifunctional protein involved in a large 
array of important cellular pathways. PP1 is an oligomeric enzyme 
that contains one catalytic subunit (encoded by PPP1CA, PPP1CB 
and PPP1CC) and at least one regulatory subunit (16 regulatory 
subunits). Importantly, PP1 plays a role in mitotic regulation,5 
glycogen metabolism and RNA splicing. In cancer, PP1 has been 
shown to play a role in the tumour microenvironment 6 and in 
steering cellular migration,7 and it has been shown to interact with 
BRCA1.8
Both PP1 and PKA can be inhibited by dopamine- and cAMP- 
regulated phosphoprotein 32 kD (DARPP- 32), also known as 
protein phosphatase one regulatory subunit 1B and encoded by 
PPP1R1B. DARPP- 32 was originally described as a signalling pro-
tein highly concentrated in regions of the brain enriched in dopa-
minergic nerve terminals.9 DARPP- 32 is able to inhibit both PKA 
and PP1 dependent upon its phosphorylation status. For instance, 
DARPP- 32 is phosphorylated on threonine 34 by PKA to allow 
it to act as a potent inhibitor of PP1.10 Cyclin- dependent kinase 
(Cdk)- 5 can phosphorylate DARPP- 32 on threonine 75 to allow it 
to act as a PKA inhibitor.11 In a variety of cancers, a truncated 
DARPP- 32 splice variant (t- DARPP) is expressed; importantly, this 
isoform lacks the ability to inhibit PP1, but retains PKA inhibitory 
activity.12 Phosphorylation of t- DARPP has been shown to medi-
ate PKA activation, which appears to be via association between 
t- DARPP and the regulatory R1 subunit.13
There is accumulating evidence that differential expression of 
DARPP- 32 and t- DARPP is functionally significant in numerous tu-
mour types (reviewed in14). Low levels of DARPP- 32 protein expres-
sion are associated with shorter cancer- specific survival of breast 
and ovarian cancer patients.15,16 In trastuzumab- resistant breast 
cancer cells, t- DARPP activated IGF- 1R signalling, which stimulated 
glycolysis and conferred trastuzumab resistance.17 In gastric cancer, 
DARPP- 32 is frequently overexpressed in the early stages of gas-
tric cancer.18 In lung cancer, DARPP- 32 and t- DARPP promoted tu-
mour cell growth in vivo and in vitro.19,20 In pancreatic cancer, loss 
of HIF1α increased PPP1R1B expression, and DARPP- 32 promoted 
degradation of p53 through phosphorylation of MDM2.21
DARPP- 32 is phosphorylated by PKA or Cdk5 to alter its inhib-
itory activity; Cdk5 is involved in neuronal maturation but is also 
implicated in cancer and neurodegenerative disorders. In breast can-
cer, low Cdk5 expression has also been shown to be associated with 
adverse survival of breast cancer patients.16
In breast cancer, we hypothesize that a reduction in DARPP- 32 
and an increase in t- DARPP in breast cancer result in a concomitant 
alteration of PKA and PP1 signalling. We sought to determine the 
expression of PKA and PP- 1 mRNA and protein in a large cohort of 
early- stage invasive breast cancer patients to understand their rela-
tionship between survival and clinicopathological criteria and to de-
termine their relationship between DARPP- 32 and Cdk5 expression.
2  | METHODS
2.1 | Patient cohorts
Breast cancer patients were all treated at Nottingham University 
Hospitals between 1998 and 2006. Patients underwent a wide 
local excision or mastectomy, decided by disease characteristics or 
patient choice, followed by radiotherapy if indicated. Nottingham 
Prognostic Index (NPI), ER and menopausal status determined if 
patients received systemic adjuvant treatment. Patients with an 
NPI score less than 3.4 did not receive adjuvant treatment, and pa-
tients with an NPI score of 3.4 and above were candidates for CMF 
combination chemotherapy (cyclophosphamide, methotrexate and 
5- fluorouracil) if they were ER- negative or pre- menopausal; and hor-
monal therapy if they were ER- positive.
PKA mRNA expression and PP- 1 mRNA expression were deter-
mined in the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) data set (n = 1980).22 DNA and RNA were 
isolated from samples and hybridized to the Affymetrix SNP 6.0 and 
Illumina HT- 12 v3 platforms for genomic and transcriptional profil-
ing as described by Curtis et al.22 Tumours were collected by five 
centres in the UK and Canada between 1977 and 2005, and almost 
all ER- negative and lymph node– positive patients received adjuvant 
chemotherapy, whereas ER- positive and/or lymph node– positive 
patient did not. No patients with HER2 overexpression received 
trastuzumab.
2.2 | Immunohistochemistry
Immunohistochemistry was performed on tissue microarrays com-
prised of single 0.6 mm cores taken from a representative tumour 
area as assessed on haematoxylin and eosin– stained sections by 
a specialist breast cancer histopathologist. Immunohistochemical 
staining was achieved using a Novolink Polymer Detection Kit 
(Leica) according to the manufacturers’ instructions, the use of 
which has been described previously. Briefly, tissue was depar-
affinized in xylene and rehydrated in ethanol followed by water. 
Antigen retrieval was performed in 0.01 mol L−1 sodium citrate 
buffer (pH 6.0), with tissue heated for 10 minutes at 750 W in a 
microwave and then 10 minutes at 450 W. Tissue was blocked with 
Novolink Peroxidase Block and then Novolink Protein Block so-
lution with Tris- buffered saline (TBS) washes in- between. Rabbit 
polyclonal PKA C- α antibody (Cell Signalling Technology #4782) 
was used at a concentration of 1:50 diluted in Bond Primary 
Antibody Diluent (Leica). Mouse monoclonal PP- 1 alpha antibody 
(clone 10C6- 3, Life technologies) was used at concentration of 
1:100 diluted in Bond Primary Antibody Diluent (Leica). Both anti-
bodies were incubated on tissue for 1 hour at room temperature, 
and antibody specificity was confirmed by Western blotting using 
breast cancer cell lysates prior to use. Following antibody incuba-
tion, tissue was washed with TBS before application of Novolink 
Post Primary solution, further TBS washes and Novolink Polymer 
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solution. Immunohistochemical reactions were developed using 
3,3′- diaminobenzidine as the chromogenic substrate and tissue 
were counterstained with haematoxylin. Tissue was dehydrated 
in ethanol and fixed in xylene prior to mounting using DPX. Breast 
tumour composite sections comprising of grade 1 and 2 early- 
stage invasive tumours were used as positive and negative con-
trols, and were included with each staining run.
2.3 | Scoring and statistical analysis
Slides were scanned at 200× magnification using a Nanozoomer 
Digital Pathology Scanner (Hamamatsu Photonics). Cytoplasmic 
staining was assessed using a semi- quantitative immunohisto-
chemical H- score, where staining intensity within tumour cells 
was assessed as none (0), weak (1), medium (2) or strong (3) over 
the percentage area of each staining intensity. Nuclear staining was 
assessed as the percentage of tumour cells that demonstrated any 
staining intensity. Greater than 30% of cores for each TMA were 
double assessed, with both assessors blinded to clinical outcome and 
each other's scores.
Statistical analysis was performed using IBM SPSS Statistics 
(version 24). X- tile was used to determine cut- points for assess-
ment using breast cancer– specific survival.23 Single measure 
intraclass correlation coefficients were used to determine concor-
dance between scorers with levels above 0.7 that indicated good 
concordance. The Pearson chi- squared test of association was 
used to determine the relationship between categorized protein 
expression and clinicopathological variables. Survival curves were 
plotted according to the Kaplan- Meier method with significance 
determined using the log- rank test. Multivariate survival analysis 
was computed using the Cox regression analysis. All differences 
were deemed statistically significant at the level of P ≤ .05. This 
study is reported according to REMARK criteria.24 Broad Institute 
Morpheus software was used to visualize data (https://softw are.
broad insti tute.org/morpheus). Expression of PKA and PP1 was 
F I G U R E  1   Heat map of DARPP- 32, 
PP1, PKA and Cdk5 expression (A). 
Representative photomicrographs of 
high (B) and low (C) PKA expression, 
and high (D) and low (E) PP1 expression 
are shown at 10× magnification with a 
20× magnification inset box. Scale bar 
represents 100 µM. Similarity matrix 
of Pearson's correlation coefficients 
between protein expression (F)
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TA B L E  1   Associations between the cytoplasmic and nuclear expression of DARPP- 32, determined in the discovery cohort and validation 
cohort using immunohistochemistry, with clinicopathological variables









<50 y 41 (3.6%) 328 (28.6%) .919 428 (25.9%) 71 (4.3%) .140 428 (25.9%) 71 (4.3%) .043
≥50 y 84 (7.3%) 695 (60.4%) 1019 (61.7%) 134 (8.1%) 1032 (62.4%) 124 (7.5%)
Tumour size
<2CM 71 (6.2%) 617 (53.7%) .499 891 (54.0%) 135 (8.2%) .242 902 (54.5%) 127 (7.7%) .371
≥2CM 54 (4.7%) 406 (35.4%) 555 (33.6%) 70 (4.2%) 557 (33.7%) 68 (4.1%)
Tumour grade
1 21 (1.8%) 144 (12.5%) .501 231 (14.0%) 30 (1.8%) .245 229 (13.8%) 32 (1.9%) .838
2 50 (4.4%) 384 (33.4%) 599 (36.3%) 75 (4.5%) 601 (36.3%) 76 (4.6%)
3 54 (4.7%) 495 (43.1%) 616 (37.3%) 100 (6.1%) 629 (38.0%) 87 (5.3%)
Tubule formation
1 12 (1.1%) 69 (6.1%) .257 104 (6.3%) 15 (0.9%) .473 103 (6.3%) 16 (14.1%) .855
2 29 (2.6%) 297 (26.1%) 418 (25.5%) 67 (4.1%) 429 (26.1%) 58 (3.5%)
3 82 (7.2%) 648 (57.0%) 914 (55.8%) 120 (87.7%) 914 (55.7%) 121 (7.4%)
Pleomorphism
1 2 (0.2%) 10 (0.9%) .084 21 (1.3%) 0 (0.0%) .031 20 (1.2%) 1 (0.1%) .594
2 43 (3.8%) 265 (23.3%) 447 (435.7%) 50 (3.1%) 439 (26.8%) 59 (3.6%)
3 78 (6.9%) 739 (65.0%) 968 (59.1%) 152 (9.3%) 987 (60.1%) 135 (8.2%)
Mitosis
1 63 (5.5%) 454 (40.0%) .233 720 (44.0%) 99 (6.1%) .012 719 (43.9%) 103 (6.3%) .050
2 18 (1.6%) 208 (18.3%) 280 (17.1%) 25 (1.5%) 281 (17.1%) 24 (1.5%)
3 42 (3.7%) 351 (30.9%) 434 (26.5%) 78 (4.8%) 444 (27.1%) 68 (4.1%)
Vascular invasion
Definite 50 (4.4%) 297 (25.9%) .012 415 (25.2%) 64 (3.9%) .461 426 (25.8%) 53 (3.2%) .614
No/probable 75 (6.5%) 726 (63.2%) 1030 (62.4) 141 (8.5%) 1033 (62.5%) 141 (8.5%)
Stage
1 74 (6.5%) 649 (56.7%) .278 926 (56.2%) 118 (7.2%) .050 931 (56.4%) 113 (6.8%) .082
2 32 (2.8%) 271 (23.7%) 376 (22.8%) 70 (4.2%) 383 (23.3%) 66 (4.0%)
3 18 (1.6%) 101 (8.8%) 141 (8.6%) 17 (1.0%) 142 (8.6%) 16 (1.0%)
Nottingham Prognostic Index
Good 37 (3.2%) 328 (28.7%) .303 515 (31.3%) 63 (3.8%) .315 516 (31.3%) 62 (3.8%) .597
Medium 60 (5.2%) 526 (46.0%) 704 (42.7%) 111 (6.7%) 716 (43.4%) 102 (6.2%)
Poor 27 (2.4%) 166 (14.5%) 223 (13.5%) 31 (1.9%) 223 (13.5%) 31 (1.9%)
ER status
Negative 21 (1.8%) 215 (18.7%) .273 274 (16.6%) 43 (2.6%) .507 281 (17.0%) 36 (2.2%) .797
Positive 104 (9.1%) 809 (70.4%) 1174 (71.0%) 162 (9.8%) 1180 (71.3%) 159 (9.6%)
PR status
Negative 52 (4.8%) 414 (38.3%) .831 579 (37.1%) 82 (5.3%) .865 586 (37.5%) 75 (4.8%) .597
Positive 66 (6.1%) 548 (50.7%) 784 (50.3%) 114 (7.3%) 790 (50.6%) 110 (7.0%)
HER2 status
Negative 105 (9.8%) 867 (80.8%) .978 1249 (80.5%) 176 (11.3%) .529 1262 (81.2%) 166 (10.7%) .251
Positive 11 (1.0%) 90 (8.4%) 108 (7.0%) 15.8 (1.2%) 107 (6.9%) 19 (1.3%)
Note: The P values are resultant from Pearson's chi- squared test of association, and significant values (P < .05) are highlighted in bold.
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compared with DARPP- 32 and Cdk5 which has been described 
previously.15,16
3  | RESULTS
3.1 | PKA and PP1 protein staining and frequency 
and correlation of expression
The majority of PKA expression was cytoplasmic with weak to strong 
staining intensity observed in tumour cells; representative staining is 
shown in Figure 1B,C. The median PKA H- score was 160 and ranged 
from 0 to 290; X- tile computed a H- score cut- point of 90, with 89.0% 
(1032/1159) cases demonstrating high expression. PP1 expression 
was observed in both the cytoplasm and the nucleus; representative 
staining is shown in Figure 1D,E. Cytoplasmic PP1 expression had a 
median H- score of 0 and ranged from 0 to 160. X- tile computed a 
H- score cut- point of 25, with 12.6% (187/1488) cases demonstrat-
ing high expression. Nuclear PP1 expression had a median H- score 
of 0 and ranged from 0 to 100. X- tile computed a H- score cut- point 
of 20, with 11.9% (178/1491) cases demonstrating high expression. 
Representative PKA and PP1 protein expression is demonstrated in 
Figure 1A.
Correlations between the expression of PKA and PP1 together 
with DARPP- 32 and Cdk5 were assessed. Many of the combina-
tions were statistically significant; however, they were of weak 
biological significance (Figure 1E). PKA expression was signifi-
cantly correlated with cytoplasmic (P = .012, R2 = .077) and nu-
clear (P = .047, R2 = .061) PP1 expression. PKA expression was 
significantly correlated with cytoplasmic (P = .030, R2 = .066) 
and nuclear (P = .014, R2 = .075) DARPP- 32 expression. PKA ex-
pression was significantly correlated with cytoplasmic (P < .001, 
R2 = .169) and nuclear (P < .001, R2 = .128) Cdk5 expression. 
Cytoplasmic PP1 expression was not significantly correlated with 
cytoplasmic (P = .410, R2 = .021) and nuclear (P = .991, R2 = .000) 
DARPP- 32 expression, but was significantly correlated with cy-
toplasmic (P < .001, R2 = .154) and nuclear (P = .025, R2 = .070) 
Cdk5 expression.
3.2 | Relationship between PKA and PP1 protein 
expression and clinicopathological criteria
Low expression of PKA was significantly associated with the pres-
ence of lymphovascular invasion (LVI) (χ2 = 6.353, df = 1, P = .012). 
PKA expression was not associated with any other clinicopathologi-
cal variables (Table 1).
Low cytoplasmic PP1 expression was associated with pleomor-
phism (χ2 = 6.918, df = 2, P = .031) and mitosis (χ2 = 8.849, df = 2, 
P = .012). Low nuclear PP1 expression was associated with older 
patient age (χ2 = 4.112, df = 1, P = .043). Nuclear and cytoplasmic 
PP1 expression was not associated with any other clinicopathologi-
cal variables (Table 1).
3.3 | Association between PKA and PP1 protein 
expression and survival
Low PKA expression was significantly associated with adverse 
survival of breast cancer patients (P = .040) (Figure 2A). Ten- year 
survival of breast cancer patients with high expression of PKA was 
82.3% (95% confidence interval (CI) = 0.768- 0.848) and low ex-
pression of PKA was 77.6% (95% CI = 0.675- 0.835). Expression of 
PKA did not remain associated with survival when potentially con-
founding factors of tumour size, grade, nodal stage, ER status, PR 
status, HER2 status, and LVI status were included in multivariate 
Cox regression analysis (P = .201; hazard ratio (HR)=0.768; 95% 
CI = 0.513- 1.151) (all with individual log- rank statistics of P < .001). 
Interestingly, a stronger association was observed between low lev-
els of PKA expression and adverse survival in ER- positive breast can-
cer patients (P = .003) (Figure 2B).
Cytoplasmic and nuclear PP- 1 protein expression was not asso-
ciated with survival of breast cancer patients (P = .217 and P = .428) 
(Figure 2C,D).
Associations between combined PKA, PP1, DARPP- 32 and 
Cdk5 expression and breast cancer– specific survival were as-
sessed. The combination of low PKA and low Cdk5 expression 
(P = .006; Figure 3B), low PP1 and low DARPP- 32 (P = .001; 
Figure 3C) and combination of low PP1 and low Cdk5 (P = .010; 
Figure 3D) showed significant association with shorter survival. 
However, the combined expression of PKA and DARPP- 32 was 
not associated with breast cancer- specific survival (P = .139) 
(Figure 3A).
3.4 | PKA and PP1 mRNA expression in the 
METABRIC cohort
PKA and PP1 mRNA expression was assessed for association 
with patient survival in the METABRIC cohort using probe- level 
information. Probe- level information was used so that correla-
tions with PPP1R1B variants could be assessed. PPP1R1B probe 
1 (ILMN_1690096) is located within a coding area that corre-
sponds to the N- terminal region of DARPP- 32; PPP1R1B probe 
2 (ILMN_1759012) and PPP1R1B probe 3 (ILMN_2304495) were 
both located in untranslated regions (5′ and 3′, respectively). 
DARPP- 32 mRNA would align with probe 1 and probe 3; t- DARPP 
mRNA would align with probe 2 and probe 3. PRKACA, PRKACB, 
PRKACG, PRKAR1A, PRKAR1B, PRKAR2A and PRKAR2B were as-
sessed for PKA and PPP1CA, PPP1CB and PPP1CC were assessed 
for PP1; heat map visualization of expression and correlation be-
tween expression is shown in Figure 4A,B.
Table 2 shows associations between probe- level information and 
patient survival in the METABRIC cohort using the Cox (proportional 
hazards) regression analysis. PRKACG, PRKAR1B and PPP1CA were 
associated with patient survival. One of five probes for PRKACB, one 
of three probes for PRKAR1A and one of two probes for PPP1CB 
were associated with patient survival.
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4  | DISCUSSION
This study investigated the expression and co- expression of four 
important signalling proteins in breast cancer and assessed their 
prognostic and clinical significance. We provide evidence that low 
expression of PKA is significantly associated with adverse survival 
of breast cancer patients in a large cohort of breast cancer patients; 
interestingly, this relationship was stronger in ER- positive breast 
cancer patients. The ER relationship is interesting, as we have made 
similar observations with DARPP- 32 expression as part of previous 
studies.15 PP1 expression was not associated with patient survival. 
Previous studies have linked DARPP- 32 and HER2- positive breast 
cancer; our current findings provide further evidence that the 
DARPP- 32 signalling nexus plays a role in breast cancer subgroups, 
in particular, in ER- positive disease.
The function of both PKA and PP1 can be inhibited by DARPP- 32 
dependent upon its phosphorylation status. DARPP- 32 can be 
phosphorylated by PKA on threonine 34 to allow PP1 inhibition or 
by Cdk5 on threonine 75 to allow inhibition of PKA. Our findings 
demonstrate that PKA expression was significantly correlated with 
DARPP- 32 and Cdk5 expression (both determined in previous stud-
ies15,16). Our findings also demonstrate that PP1 expression was sig-
nificantly correlated with previously determined Cdk5 expression, 
but not DARPP- 32 expression. It is important to note that this study 
assessed the expression level of PKA and PP1 protein and mRNA 
and inference on cellular activity cannot be made. PP1 expression 
was assessed in both the cytoplasm and the nucleus, whereas PKA 
was only observed in the cytoplasm. Neither PP1 nuclear or cyto-
plasmic expression was associated with patient survival; however, 
different associations were observed with clinicopathological vari-
ables. Cytoplasmic PP1 was associated with pleomorphism and 
mitosis, indicating an association with altered cell growth, whereas 
nuclear PP1 was associated with patient age, studies have indicated 
differential subcellular localization.25
In addition to protein expression, mRNA expression of PKA and 
PP1 subunits was assessed, including PRKACA, PRKACB, PRKACG, 
PRKAR1A, PRKAR1B, PRKAR2A and PRKAR2B, for PKA and PPP1CA, 
PPP1CB and PPP1CC for PP1. Probe- level information was assessed 
so that correlations could be made with represented PPP1R1B vari-
ants in the data set. Expression of the three PPP1R1B probes were 
closely related; however, no strong biologically relevant association 
was observed between expression of the PPP1R1B probes and other 
probes assessed in this study.
PRKACG, PRKAR1B and PPP1CA were the most strongly and re-
producibly associated with breast cancer– specific survival. There 
were other significant associations between specific probes and 
survival; one of five probes of PRKACB, one of three probes for 
PRKAR1A and one of two probes for PPP1CB PRKACB, PRKAR1A 
and PPP1CB have multiple splice variants, and the observation that 
not all probes are associated with survival, may indicate that certain 
transcripts are more important in breast cancer and warrants further 
investigation.
F I G U R E  2   Kaplan- Meier analysis of PKA (A) and PKA expression in oestrogen receptor– positive breast cancer (B) and cytoplasmic (C) 
and nuclear (D) PP1 expression where the impact of low (grey line) and high (black line) expression is shown
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In breast cancer, low PRKAR1A expression in combination with 
high SRC expression has been shown to be associated with basal- 
like and HER2- positive breast cancer associated with poor survival,3 
and in HER2- resistant breast cancer, down- regulation of PRKAR2A 
and PRKAR2B has been observed, in combination with an observed 
increase with PPP1R1B.4 Our findings suggest that PRKAR1B and 
PRKACG were associated with disease- specific survival of the total 
patient cohort.
Our findings suggest that PPP1CA, PRKACG and PRKAR1B are as-
sociated with breast cancer– specific survival. Previously published 
studies have indicated a role for PPP1CA in cancer26,27; in breast 
cancer, PPP1CA may play a role in cancer stem cell populations.28 
Although a role for PRKACG and PRKAR1B in breast cancer has 
not been described, PRKACG has been shown to act as a RUNX1- 
mutation associated hub gene in acute myeloid leukaemia29 and 
single nucleotide polymorphisms of PRKAR1B are associated with 
inferior survival of advanced renal cell cancer patients.30
In previous studies, we demonstrated that low DARPP- 32 and 
Cdk5 expression is associated with adverse survival of breast can-
cer patients.15,16 We hypothesized that a reduction in DARPP- 32 
and an increase in t- DARPP in breast cancer result in a concomitant 
alteration of PKA and PP1 signalling. In this study, we explored as-
sociations between PKA, PP1, DARPP- 32 and Cdk5 expression and 
breast cancer– specific survival. The combination of PKA and Cdk5 
expression was significantly associated with survival as was the com-
bined expression of PP1 and DARPP- 32 and the combined expres-
sion of PP1 and Cdk5. In patients with high expression of DARPP- 32, 
low expression of PP1 was associated with adverse survival when 
compared to high expression in the same group. In patients with high 
expression of Cdk5, high expression of PKA was associated with 
adverse survival when compared with low expression in the same 
subgroup; low expression of PP1 was significantly associated with 
adverse survival when compared with high expression in the same 
subgroup. These findings warrant further functional investigation 
of the DARPP- 32 signalling nexus in breast cancer, with a particular 
focus in ER- positive disease.
5  | CONCLUSION
Low PKA expression was significantly associated with adverse sur-
vival of breast cancer patients in a large cohort of breast cancer 
F I G U R E  3   Kaplan- Meier analysis of combined protein expression. A, PKA and cytoplasmic DARPP- 32 expression; high PKA and high 
DARPP- 32 (orange), high PKA and low DARPP- 32 (green), low PKA and high DARPP- 32 (pink) and low PKA and low DARPP- 32 (blue) are 
shown. B, PKA and cytoplasmic Cdk5 expression; high PKA and high Cdk5 (orange), high PKA and low Cdk5 (pink), low PKA and high Cdk5 
(green) and low PKA and low Cdk5 (blue) are shown. C, PP1 and cytoplasmic DARPP- 32 expression; high PP1 and high DARPP- 32 (orange), 
high PP1 and low DARPP- 32 (green), low PP1 and high DARPP- 32 (pink) and low PP1 and low DARPP- 32 (blue) are shown. D, PP1 and Cdk5 
expression; high PP1 and high Cdk5 (orange), high PP1 and low Cdk5 (pink), low PP1 and high Cdk5 (green) and low PP1 and low Cdk5 (blue) 
are shown
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patients; interestingly, this relationship was stronger in ER- positive 
breast cancer patients. PP1 protein expression was not associated 
with patient survival. PKA and PP1 subunit mRNA expression was 
also assessed; PPP1CA, PRKACG and PRKAR1B were associated with 
breast cancer– specific survival. PKA expression and PP1 expression 
are of significant interest in cancer as they are involved in a wide 
array of cellular processes and may play an important role in patient 
outcome.
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hazard ratio are shown. Significant results are highlighted in bold.
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